AEterna Zentaris Inc. Stock News

Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 9.) * Arcutis Biotherapeutics Inc (NASDAQ: ARQT) * Enz

Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 2) * Forty Seven Inc (NASDAQ: FTSV)( announced a dea

Additionally, the Company issued to the investors unregistered warrants to purchase up to an aggregate of 2,608,696 common shares in a concurrent private placement. The warrants have an exercise pric

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 19) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Akebia

The offering is expected to result in gross proceeds to Aeterna Zentaris of approximately $4.5 million. Aeterna Zentaris will also issue to the purchasers unregistered warrants to purchase up to an a

As part of his presentation, Dr. Paulini will provide a corporate overview and update on the Company’s lead product, Macrilen™ (macimorelin), the only U.S. FDA and European Commission approved ora

– Study P01 is the first of two studies as agreed with the EMA in the Company’s Pediatric Investigation Plan for macimorelin as a growth hormone deficiency diagnostic – – Study.

CHARLESTON, S.C., Jan. 27, 2020 -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company engaged in.